Purpose: TAS-108 is a novel steroidal anti-estrogen compound that has a strong binding affinity to the estrogen receptor and, in preclinical studies, has antitumor activity against tamoxifen-resistant breast cancer cell lines. The objective of this study was to investigate the safety and the pharmacokinetics in patients with previously treated advanced breast cancer.
INTRODUCTION
There are 217,440 cases of new breast cancer estimated this year with ϳ40,110 deaths (1). Many chemotherapeutic and hormone therapies have been used to treat breast cancer in the neo-adjuvant and adjuvant setting as well as to prevent breast cancer. Tamoxifen is a selective estrogen receptor modulator (SERM) that has been shown to be effective in treating metastatic disease in women with estrogen receptor-positive breast cancer regardless of menopausal status (2, 3) . Tamoxifen is also used in the adjuvant setting in postmenopausal women with estrogen receptor-positive breast cancer after surgery (2, 3) . Recently tamoxifen has also been shown as an effective agent in the prevention for breast cancer in high-risk populations (4) . Tamoxifen has an agonistic activity that is beneficial for protection against bone loss (5); however, this agonistic effect also can be harmful with an increase in the incidence of endometrial cancer and thromboembolic events seen with the use of tamoxifen (6, 7) .
Many have begun to investigate aromatase inhibitors and selective estrogen receptor down-regulator (SERD) to overcome the clinical limitations of tamoxifen. Aromatase inhibitors have been shown to be clinically superior to tamoxifen with time to progression for postmenopausal women with estrogen receptorpositive breast cancer (8 -12) . These drugs do not have agonistic properties and, therefore, do not have the same risk of endometrial cancer with long-term use as does tamoxifen. What is unclear is whether the steroidal aromatase inhibitors and SERD will have the same protective effect on bone mineral density as does tamoxifen, because nonsteroidal aromatase inhibitors are associated with an increased risk of bone loss (13, 14) . Also, aromatase inhibitors, although superior clinically to tamoxifen, cannot be used in premenopausal women without complete estrogen blockade with luteinizing hormone-releasing hormone.
TAS-108 was developed to find a ligand for estrogen receptor ␣ and/or ␤, which might be clinically more beneficial than tamoxifen, aromatase inhibitors, and SERD. TAS-108, (7␣)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate, is a novel steroidal molecule developed in collaboration between Taiho Pharmaceutical Co., Ltd., and SRI International. TAS-108 has been shown to be a strong binding ligand to estrogen receptor with recruitment of a specific cofactor to estrogen receptor ␤ (15). It was shown that TAS-108 acts with molecular mechanisms that are different from those of tamoxifen or SERD (16) . TAS-108 showed tissue-selective agonist activity in the bone and cardiovascular systems (17) .
In preclinical studies, TAS-108 was shown to have antitumor activity with increased binding affinity when compared with tamoxifen and fulvestrant. TAS-108 was found to be active in the tamoxifen-sensitive MCF-7 cell line and resistant cell lines FST-1, KPL-1, and LY-2. TAS-108 was shown to inhibit the decrease in bone mineral density in estrogen-deprived rat models, which suggests agonistic activity; however, when tested, TAS-108 was found to have antagonistic activity in estrogen-stimulated uterine tissue in animal models. TAS-108 was found to have no serious toxicities in animal studies and, in a phase I study that was made in healthy postmenopausal women, showed no serious adverse events or dose-dependent increases in adverse events. Side effects from that study included mild nausea, arthralgia, muscle cramps, and moderate back and limb pain. 3 The data of that study indicated that most patients treated at the 10-and 20-mg dose levels had levels of TAS-108 below the limit of quantifications, but at the 40-mg dose level, TAS-108 levels were detectable. The 40-mg dose was the starting dose for the phase I study reported here; preliminary results of this study were reported at the 94 th Annual Meeting of the American Association of Cancer Research (18) .
PATIENTS AND METHODS
Patient Selection. Postmenopausal women over the age of 18 were eligible for this study. "Postmenopausal" was defined as no spontaneous menses for a total of 5 years, amenorrheic for at least 12 months with serum estrogen level Ͻ30 pg/mL, and both luteinizing hormone and follicle-stimulating hormone values Ͼ20 IU/L, chemotherapy induced amenorrhea for at least 12 months, bilateral oophorectomy, or radiation castration and amenorrheic for at least 3 months (except for luteinizing hormone-releasing hormone agonist-induced amenorrhea). Other eligibility criteria included the following: histologically or cytologically confirmed breast cancer; locally advanced or locally recurrent inoperable or metastatic breast cancer; laboratory documentation of positive estrogen receptor and/or progesterone receptor status or previous endocrine therapy for advanced disease with biological antitumor activity; Zubrod performance status of 0 to 2; life expectancy Ն12 weeks; measurable and/or evaluable disease; adequate bone marrow function; adequate liver function (defined as absolute granulocyte count Ͼ1500/L; platelet count Ͼ75,000/L; and hemoglobin Ͼ10.0 g/dl), and adequate renal function (defined as bilirubin and creatinine Ͻ1.5 times the upper limit of normal; transaminases Ͻ2.5 times the upper limit of normal (if liver metastasis was present then transaminases needed to be Ͻ5 times the upper limit of normal)].
Patients were required to have received and failed at least two or more prior systemic antitumor therapies with at least one of these therapies having been an endocrine therapy. Patients who had received previous investigational therapies had to be off those therapies for at least 4 weeks before treatment with TAS-108. Patients also had to have recovered from all previous anticancer treatment-related toxicities to at least grade 1. It was preferred that patients be off prior chemotherapy for at least 4 weeks and prior endocrine therapy for at least 3 weeks. Patients with inflammatory breast cancer were excluded from the study, as were patients with symptomatic brain metastasis, extensive liver involvement, or lymphangitic lung involvement. Patients who had been taking supplemental estrogen or progesterone within 3 weeks of the start of the study were also excluded. All of the patients gave written informed consent as per institutional and federal regulatory requirements. The institutional review board approved the study. Study Design. This was a phase I, open-label, nonrandomized, dose-finding study of TAS-108. The study evaluated the safety and the pharmacokinetics of TAS-108 when administered orally in postmenopausal women with advanced breast cancer. Taiho Pharmaceutical Co., Ltd., Tokyo, Japan, supplied TAS-108. Patients were enrolled in five escalating dose groups: 40 mg, 60 mg, 80 mg, 120 mg, and 160 mg dosages ( Table 1) . The study drug was given orally and once daily in each of the five dose levels.
A minimum of three patients were enrolled in each dose level. If there were no drug related grade 3 or higher toxicities in the first 14 days of treatment in the first three patients, escalation to the next dose started. If grade 3 or higher drugrelated toxicities were seen in one of the first three patients, three more patients were planned to be enrolled in that dose level. The maximum tolerated dose of TAS-108 was defined as one dose level below the dose at which two or more of the first three patients or of the total of six patients experienced grade 3 or higher drug-related toxicities. NCI CTC version 2.0 (National Cancer Institute Common Toxicity Criteria, NIH, Bethesda, MD) was used for grading drug-related toxicities. Patients remained on TAS-108 at their designated dose level until disease progression or until unacceptable toxicity occurred.
Pharmacokinetics. Blood samples (3 ml) were collected in heparinized tubes before the first dose of TAS-108 and at 2, 4, 6, 8, 10, 12, 14, and 24 h thereafter on day 1. Blood samples were also collected at day 15 before the dose of TAS-108 and on day 28 before and at 6 and 12 h after TAS-108 during course 1 to determine the pharmacokinetic data for TAS-108 and the active metabolite, deEt-TAS-108. These samples were placed on ice and transported to the laboratory at which the samples were centrifuged and the plasma stored at Ϫ70°C. The samples 3 Unpublished data from Taiho Pharmaceutical Co., Ltd., Tokyo, Japan. were then shipped to Northwest Bioanalytical in Salt Lake City, Utah, where the plasma concentrations of TAS-108 and deEt-TAS-108 were determined. TAS-108 and deEt-TAS-108 plasma concentrations were analyzed using noncompartmental techniques. For each patient consenting to pharmacokinetic blood sampling, the maximum observed plasma concentration (C max ), time to maximum plasma concentration (t max ), area under the curve from hour 0 to last measurable plasma concentration (AUC 0-t ), area under the plasma concentration-time curve extrapolated to infinity (AUC 0-ϱ ), plasma terminal elimination half-life (t 1/2 ), and apparent oral clearance (CL/F) were ob- 
Abbreviations: CTC, National Cancer Institute Common Toxicity Criteria. tained. Because the concentration-time profile showed a multiphasic elimination process, the elimination half-life were computed for 6-to 12-hour and 12-to 24-hour intervals. One patient underwent a tumor biopsy on day 28 of the fifth course, and two pieces of tumor tissue were obtained. The tumor samples were stored at Ϫ70°C, and the samples were shipped to the laboratory of Taiho Pharmaceutical Co., Ltd., Tokushima, Japan. There, tumor samples were pretreated for analysis and then were shipped to Toray Research Laboratory, Kanagawa, Japan, where the concentrations of TAS-108 and deEt-TAS-108 were determined in both the tumor and the blood samples in this patient. In a preclinical study, 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumor-bearing rats were given [
14 C]TAS-108 orally, synthesized by Daiichi Pure Chemicals Co., Ltd., at a dose of 10 mg/kg. Plasma and tumor were collected at the scheduled time from the rats. Composition of TAS-108 and its metabolite in the plasma and tumor was determined by those radioactivities in high-performance liquid chromatography analysis.
Patient Evaluation. A complete medical history was obtained from all of the patients, and all underwent a physical examination before enrollment into the study. Patients had repeat physical examinations at the end of each course of treatment during their follow-up clinic visits. Laboratory analyses such as complete blood count, serum electrolytes (total protein, albumin, calcium, phosphorus, glucose, blood urea nitrogen, creatinine, bilirubin, lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, sodium potassium, chloride, total cholesterol, and triglycerides), urinalysis, serum hormone levels (testosterone, follicle-stimulating hormone, thyroid-stimulating hormone, cortisol, prolactin, estrone, 17␤-estradiol, estriol, luteinizing hormone, and sex hormone-binding globulin), tumor markers [carcinoembryonic antigen (CEA) and CA15-3], and bone markers (serum osteocalcin and type I collagen fragments) were performed before enrollment. Imaging studies such as chest radiographs, computed tomography scans, transvaginal ultrasound, and electrocardiogram were also performed before patients enrolled on study. Tests for complete blood counts, serum chemistries, urinalysis, tumor markers, and bone markers were repeated at the end of each course (defined as four weeks of treatment with TAS-108) before the start of the subsequent course. Imaging studies were done at the discretion of the investigator at the end of courses 1 and 2; however, they were done in all cases at the end of course 3 to evaluate tumor response. Likewise, a transvaginal ultrasound was performed at the end of course 3. For patients who continued treatment after course 3, a transvaginal ultrasound was performed after every four courses of treatment starting at course 3, and the same radiographic method used initially to demonstrate measurable or evaluable disease was repeated every two courses after the third course to evaluate response to TAS-108. Patients achieving a partial or complete response were to have undergone repeat imaging to confirm response 4 weeks after initial documentation.
RESULTS
Patient Characteristics. A total of 16 patients were enrolled in the five dose levels ( Table 2 ). Most patients (81%) had bone as their site of disease, performance status was 1 or 2, and median age was 57 years. Most patients were heavily pretreated, 
NOTE. Values are mean (SD).
Abbreviations: C max , maximum observed plasma concentration; t max , time to maximum plasma concentration; AUC 0-t , area under the curve from hour 0 to last measurable plasma concentration; AUC 0-ϱ , area under the plasma concentration-time curve extrapolated to infinity; t 1/2 (6 -12 h), plasma terminal elimination half-life for 6-to 12-hour intervals; t 1/2 (12-24 h), plasma terminal elimination half-life for 12-to 24-hour intervals; CL/F, apparent oral clearance; N/A not applicable; N/C, not calculated. with the majority of patients receiving three or more prior chemotherapy regimens (62.5%) and three or more endocrine therapies (75%) before starting to receive TAS-108 (see Table  3 ). All but one patient participated in the pharmacokinetic analysis, and toxicity and response data were obtained in all 16 patients.
Safety Profile. Table 4 summarizes the toxicity seen with TAS-108. No maximum tolerated dose was observed during the study.
Nine patients experienced grade 1 or 2 hot flashes. Seven patients experienced grade 1 or 2 nausea, and four patients had grade 1 or 2 vomiting; one patient experienced grade 3 nausea. Four patients experienced grade 1 or 2 sweating and 11 patients had grade 1 or 2 headache. One patient had grade 1 dizziness, and one patient had grade 2 dizziness. Three patients experienced grade 1 or 2 fatigue, and one patient had grade 3 fatigue. One patient experienced grade 3 tinnitus, and one patient had a seizure while on TAS-108; however, this patient was also receiving other medications known to lower the seizure threshold.
Transvaginal ultrasounds were performed in the eight patients who had not had previous hysterectomy (Table 5 ). The ultrasounds measured the endometrial thickness at baseline and then 4 to 12 weeks posttreatment. There was no difference between the baseline and posttreatment endometrial thickness, suggesting that TAS-108 has no effect on the endometrial lining.
TAS-108 had no effect on liver function tests, cholesterol, thyroid function tests, or electrolytes. There were no hematologic effects seen with TAS-108.
Pharmacokinetics. All but one patient consented to pharmacokinetic blood testing. All pharmacokinetic data were obtained during course 1 of therapy with TAS-108. Table 6 summarizes the pharmacokinetic data for TAS-108 and its metabolites. TAS-108 was rapidly absorbed and reached a mean t max at 2.7 to 5.3 hours after the dose. The concentration-time profile showed a multiphasic elimination process. The mean terminal half-life ranged from 8.0 to 10.7 hours in the interval of 12 to 24 hours after the dose. The mean C max ranged from 2.8 to 21.0 ng/mL and AUC 0-t from 15.1 to 148.7 ng⅐h/mL; this showed a linear correlation with the dose (Fig. 1) . There was no unusual accumulation after multiple-day dosing. Plasma and tumor concentration comparisons were available for one patient who underwent a biopsy after administration of TAS-108. This showed that concentrations in the tumor were higher in the tumor than in plasma, which was similar to what was seen in preclinical animal studies ( Fig. 2; Table 7 ).
Tumor Response. Response data were available for all patients, and response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Table 8 summarizes the responses seen with TAS-108. No patients had partial or complete response. Eight patients treated had stable disease for 11-60 weeks on study, and of those, one patient maintained stable disease for 33 weeks on therapy and another had stable disease for a total of 60 weeks on therapy with TAS-108 (Table 3) . Eight patients had progressive disease.
DISCUSSION
Antiestrogens play a major role in the treatment of both early and advanced breast cancer. The limitation of current antiestrogen therapy is that there are also associated agonistic properties with an increased incidence of endometrial cancer and thromboembolic events (6, 7) . TAS-108 is a novel steroidal anti-estrogen compound that, in preclinical studies, did not show any effect on the endometrium. The present study was the first study performed with TAS-108 with doses ranging from 40 to 160 milligrams to determine the safety and pharmacokinetics of TAS-108 in women who had previously been treated with advanced breast cancer. From preclinical studies it is known that TAS-108 is a strong binding ligand to the estrogen receptor and recruits a specific cofactor to estrogen receptor ␤ (15). In animal studies, it was shown that TAS-108 was effective against tamoxifen-sensitive and resistant breast tumors. Furthermore, TAS-108 had a positive effect on bone mineral density and had no pathological effect in endometrial tissue in animal models.
In our study, TAS-108 was well tolerated in the doses studied with no maximum tolerated dose. Some toxicities were seen, mainly hot flashes, headache, and nausea and vomiting. However, the incidences of those toxicities were not correlated with the dosage or exposure. There were no laboratory effects seen with TAS-108. We were also able to demonstrate with transvaginal ultrasound, performed in eight patients, that TAS-108 had no effect on the endometrial lining. The drug has linear pharmacokinetics, which was shown in Fig. 1 . Although no patients had complete or partial response, in this heavily treated patient population there was evidence of biological antitumor activity, with stable disease noted in 8 of the 16 patients treated. Because stable disease was seen in all dose levels, it suggests the flat dose-response curve of TAS-108 in the range of the 40-to-160-mg dose.
Because this drug was well tolerated, the toxicity was predictable and there was evidence of antitumor activity in heavily pretreated postmenopausal women, a multi-institutional phase II study for dose finding is planned to determine an optimal dose for phase III studies.
If further evidence is shown during future trials, TAS-108 may become an endocrine therapy for advanced breast cancer without risk of endometrial hyperplasia and may have a benefit for bone mineral density as well. Currently, tamoxifen is one of the few options for hormonal therapy in premenopausal women with advanced breast cancer; however, it is known to cause increased risk for endometrial cancer. If TAS-108 shows a favorable therapeutic index, there may be a role for its use not only in postmenopausal breast cancer patients but also in premenopausal breast cancer patients. NOTE. The tumor concentration profiles of TAS-108 and its metabolite in human subjects were similar to the profiles observed in rats. The concentrations of TAS-108 and deEt-TAS-108 in tumor were higher than those in plasma in both humans and rats.
‫ء‬ For human data, the plasma concentrations at 6 hours and 12 hours were averaged to extrapolate the concentrations at 9 hours after the administration of the dose.
† Plasma concentrations on day 28 of first course. ‡ Tissue concentrations on day 28 of fifth course. ‫ء‬ One of these patients was on TAS-108 treatment for a total of 60 weeks.
